Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2012

View Archived Issues

First clinical data disclosed on new beta-secretase 1 inhibitor for Alzheimer's disease

Researchers at Boehringer Ingelheim patent new CXCR2 receptor antagonists

Novel protein kinase inhibitors synthesized at Bayer Schering Pharma

Novel data disclosed on Esteve drugs for pain

Epizyme scientists disclose new DOT1-like protein inhibitors

New GlyT1 inhibitors presented

Novel neprilysin inhibitors discovered at Theravance

Taisho Pharmaceutical develops new orexin receptor antagonists

Abbott designs new antiviral agents

Amicus and GSK expand collaboration

Agios Pharmaceuticals patents novel PKM2 activators

Convergence Pharmaceuticals plans phase change for CNV-2197944

Novel product reduces accumulation of oligomeric beta-amyloid in brain

Chugai submits NDA for ibandronate sodium hydrate

Dosing begins in BB3 acute myocardial infarction study

AMAG Pharmaceuticals reports preliminary data from IDA-301 trial

First clinical trials assess TOL-101 for preventing kidney transplant rejection

Novavax and PATH partner to develop RSV vaccine for maternal immunization

Alexza reports on Adasuve MAA

Pluristem engages CPC for phase II trial of PLX-PAD

Sanofi enters collaboration with Brigham and Women's Hospital

Infinity Pharmaceuticals regains rights to PI3K, FAAH and early discovery programs

EMA to review MAA for bazedoxifene/conjugated estrogens

Royal Melbourne Institute of Technology to research use of BioDiem's LAIV for noninfluenza vaccines

Phase III trial of rebamipide ophthalmic suspension begins

New S100-A4-neutralizing antibody is a potential therapy and biomarker for cancer

Aeras and IAVI expand vaccine research partnership

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...